Oncovin (Vincristine Sulfate)

Vincristine, the active ingredient in Oncovin, is a Vinca alkaloid presented as an injectable solution for intravenous use. It is classified as an antineoplastic agent and is employed in the treatment of several pediatric and adult cancers, including leukemias and lymphomas.

GNH USA supplies Oncovin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Vincristine is used in oncology to disrupt microtubule formation in rapidly dividing cancer cells.

Acute lymphoblastic leukemia: induces remission as part of multi‑agent protocols. Hodgkin lymphoma: improves response rates when combined with other chemotherapeutics. Non‑Hodgkin lymphoma: contributes to disease control in various subtypes. Rhabdomyosarcoma: forms a key component of combination therapy for pediatric patients. Neuroblastoma: used in high‑risk treatment regimens to enhance survival outcomes.

Vincristine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Peripheral neuropathy: tingling or numbness in extremities. - Constipation: reduced bowel motility. - Alopecia: hair loss. - Nausea: mild to moderate upset stomach. - Fatigue: generalized tiredness. - Mild neutropenia: slight reduction in white blood cells.

Serious or Rare Side Effects: - Severe neutropenia: significant infection risk. - Anaphylactic reactions: potential life‑threatening allergy. - SIADH: inappropriate antidiuretic hormone secretion. - Severe peripheral neuropathy: disabling nerve damage. - Tumor lysis syndrome: rapid tumor breakdown. - Cardiac arrhythmias: irregular heart rhythm.

Vincristine requires careful monitoring and specific safety measures.

Pregnancy: category D – avoid unless benefits outweigh risks. Neonatal exposure: monitor for neurotoxicity. Renal impairment: adjust monitoring and dosing as needed. Concomitant neurotoxic drugs: avoid or monitor closely. Hematologic monitoring: perform regular complete blood counts. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vincristine interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., azole antifungals): increase toxicity. - CYP3A4 inducers (e.g., rifampin): reduce efficacy. - Other neurotoxic agents (e.g., vinblastine): heighten neuropathy risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): may have altered plasma levels. - Anticholinergic agents: can worsen constipation. - Myelosuppressive drugs (e.g., cyclophosphamide): require blood count monitoring.